Provectus Pharmaceuticals Inc. Receives Patent Protection Notices In Europe And Taiwan
KNOXVILLE, Tenn., Dec. 13 /PRNewswire/ -- Provectus Pharmaceuticals, Inc. announced today it has received allowance of two patent applications protecting its flagship products, Provecta(TM) and Xantryl(TM), from the European Patent Office (EPO) and the Intellectual Property Office of Taiwan (TIPO).
The pending patents cover certain formulations and medical uses of Provecta, a novel formulation of rose bengal, also called PV-10, as a medicament for treatment of cancer and other serious diseases, and Xantryl, a topical photoactive gel used to treat acute psoriasis and other chronic skin diseases.
The Company is seeking protection of its assets in key markets worldwide, notes Provectus CEO Craig Dees, Ph.D. The two allowances are the Company's first international cases covering these product families to have completed prosecution.
"As we successfully complete clinical trials for both products and for a number of different indications, we believe that aggressively protecting those intellectual assets will be vital to our eventual marketing success," said Dees. "These allowances validate the value of our science and our global intellectual property strategy to build value for our shareholders."
About Provectus Pharmaceuticals Inc
Provectus Pharmaceuticals, Inc. is a pioneering pharmaceutical company actively engaged in the design and development of pharmaceutical technologies for the treatment of metastatic melanoma, breast cancer and liver cancer. In addition, Provectus is preparing to begin Phase 2 clinical studies for the Company's topical agent Xantryl for psoriasis.
The Company's offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931; telephone: 865-769-4011.
For more information, contact the Company at info@pvct.com or visit the corporate Web site: http://www.pvct.com.
This release and others statements issued or made from time to time by the company or its representatives contain comments that may constitute forward- looking statements. Those include statements regarding the intent, belief or current expectations of the company and members of its management teams, as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward- looking statements.
Provectus Pharmaceuticals, Inc.CONTACT: Matt Clawson (investors), Allen & Caron Inc, +1-949-474-4300, ormatt@allencaron.com; or Peter Culpepper, of Provectus Pharmaceuticals Inc,+1-865-769-4011, or culpepper@pvct.com
Web site: http://www.pvct.com/